ARTHEx Biotech’s website
4 known investors
Arthex Biotech develops an investigational anti-miR therapeutic targeting an upregulated miRNA for the treatment of myotonic dystrophy, aiming to address the root cause of the disease. Its lead program uses an oligonucleotide conjugated to a fatty acid to improve delivery to muscle tissue at low active doses.